Other Cellbxhealth partners with AdventHealth on CTCbased monitoring in two major cancer studies PharmaTimesParsortix platform to support minimally invasive analysis across various cancer trialsOncologyRead full story pharminent May 18, 2026 (Last updated: May 21, 2026) PharmaTimes Parsortix platform to support minimally invasive analysis across various cancer trials Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA approves Enhertu for two HER2-positive early breast cancer indicationsNext: Another LAG-3 setback as Regeneron drug fails phase 3 trial Related Stories Other 225: An Interview With Craig Martin, Founder and CEO of the Orphan Therapeutics Accelerator pharminent May 18, 2026 Other ‘Seismic shift’ as obesity overtakes cancer for R&D returns pharminent May 5, 2026 Other 223: An Interview With Dr. Antn Blatnik on the Molecular Mechanisms Driving Neuromuscular Disease pharminent May 4, 2026
